SOLMUCOL ® - Acetylcysteine

SOLMUCOL ® is a drug based on acetylcysteine

THERAPEUTIC GROUP: Mucolytics

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications SOLMUCOL ® - Acetylcysteine

SOLMUCOL ® is indicated for the treatment of acute and chronic diseases of the respiratory system, characterized by hypersecretion of thick and viscous mucus.

Mechanism of action SOLMUCOL ® - Acetylcysteine

SOLMUCOL ® is a drug based on Acetylcysteine, an active ingredient counted among the mucolytics but also with an impressive antioxidant action.

Taken orally it is absorbed by the enteric mucosa and through the circulatory stream it concentrates mainly at the pulmonary level where it performs its therapeutic action both interacting with the glycoproteins constituting the mucus, breaking up the disulfide bridges so as to break up the consistency, making the secretions less dense and compact, both by supplying the cell with a key amino acid, such as cysteine, which is important in reconstituting one of the main endogenous antioxidants such as glutathione.

The aforementioned regenerative effect plays a key role in the protection of oxidative damage induced by reactive oxygen species, protecting cells from events such as lipopersidation, responsible for a significant functional deterioration.

After its activity, acetylcysteine and its derivatives are eliminated mainly via the kidneys.

Studies carried out and clinical efficacy

ACETYLCISTEIN AND PROTECTION OF HEPATIC DAMAGE

Indian J Gastroenterol. 2013 Mar 10.

Yet another study that tests the effectiveness of acetylcysteine in protecting the body from damage induced by reactive oxygen species, demonstrating how this active ingredient can protect the liver from hepatocellular necrosis induced by pushed oxidative processes.

ACETYLCISTEIN IN THE ERADICATION OF HELICOBACTER PYLORI

Minerva Gastroenterol Dietol. 2013 Mar; 59 (1): 107-12.

Interesting study that suggests a potential role of acetylcysteine in the eradication of Helicobacter Pylori, not through a direct antibiotic action, but for its ability to improve the mucosal permeability to the antibiotic, optimizing its effectiveness.

ACETYLCISTEIN IN THE PROTECTION OF DAMAGE due to ischemia REPERFUSION

Cell Biochem Funct. 2013 Apr 16. doi: 10.1002 / cbf.2967. [Epub ahead of print]

Study that emphasizes the strong antioxidant power of acetylcysteine, such as to reduce the oxidative damage induced by ischemia-reperfusion at the level of the bladder, preserving its containing and contractile capacities.

Method of use and dosage

SOLMUCOL ®

Granules for oral solution of 200-400 - 600 mg of Acetylcysteine;

Orosoluble tablets of 100 - 200 mg of acetylcysteine;

Acetylcysteine 100 mg syrup per 5 ml of solution.

Dosage and duration of therapy should be defined by your doctor based on the physical characteristics of the patient, his general state of health and the severity of his clinical picture.

In any case, the duration should never exceed 10 days, unless the doctor defines a useful therapeutic protocol in the course of chronic rhinitis.

Warnings SOLMUCOL ® - Acetylcysteine

SOLMUCOL ® therapy should necessarily be defined and supervised by your doctor in order to optimize its effectiveness while reducing the potential side effects.

It is important during therapy with acetylcysteine that the patient can expectorate adequately, in order to eliminate the bronchial secretions fludified by the active principle, thus avoiding potentially dangerous retentions due to the overlapping of bacterial infections.

Particular caution when administering SOLMUCOL ® should be reserved for patients suffering from gastro-duodenal ulcer, bronchial asthma and kidney failure.

PREGNANCY AND BREASTFEEDING

Although experimental studies do not reveal any side effects that are particularly relevant to the health of the fetus, the absence of clinical trials able to characterize the safety profile of acetylcysteine for the exposed fetus, extend the aforementioned contraindications to the use of SOLMUCOL ® also to pregnancy and the subsequent breastfeeding period.

Interactions

In order to preserve the efficacy and safety of acetylcysteine it would be advisable for the patient receiving SOLMUCOL ® to avoid the concomitant use of drugs capable of reducing expectorant abilities and of active ingredients containing thiol groups such as antibiotics.

Contraindications SOLMUCOL ® - Acetylcysteine

The use of SOLMUCOL ® is contraindicated in children under the age of 2 years and in patients hypersensitive to the active substance or to one of its excipients.

Undesirable effects - Side effects

The use of SOLMUCOL ® could cause the appearance of nausea, vomiting, bronchial obstruction and only rarely hypersensitivity reactions, both skin and respiratory.